

# Synthesis of a cyclic isostere of $\alpha$ -methyl homoserine by a stereoselective acylation–alkylation sequence of a chiral $\gamma$ -lactam

Annafelicia Civitavecchia · Gianluca Martelli ·  
Mario Orena · Samuele Rinaldi

Received: 16 September 2013 / Accepted: 9 January 2014  
© Springer-Verlag Wien 2014

**Abstract** Starting from a chiral 4-hydroxymethyl pyrrolidin-2-one, an isostere of  $\alpha$ -methyl homoserine tethered on a  $\gamma$ -lactam ring was prepared exploiting a stereoselective acylation–methylation sequence, followed by Curtius rearrangement, and structural assignment was confirmed by n.O.e. experiments. By reverting the sequence, the 3-carboxy-3-methyl derivative having the opposite configuration at C-3 was obtained with total stereoselection, but Curtius rearrangement invariably afforded only inseparable mixtures of decomposition products.

**Keywords** Conformational constriction · Amino acids · Lactams · Alkylation · Stereoselection

## Introduction

Biologically active peptides are molecules endowed with high therapeutic potential. However, they are scarcely used as drugs owing to their conformational flexibility that contributes to their promiscuous selectivity, high proteolytic susceptibility, limited cellular permeability, low bioavailability, and fast clearance (Hanessian and Auzzas 2008). Structural rigidification through lactam ring (Freidinger 2003; Perdih and Kikelj 2006; Dolbeare et al. 2003; Galaud and Lubell 2005; Broadrup et al. 2005; Seufert et al. 2006; Otvos et al. 2007; Jamieson et al. 2009; Lesma et al. 2009; Virlovet and Podlech 2010; St-Cyr et al. 2010; Boy et al. 2011) or quaternary carbon introduction (Benedetti 1996; Toniolo et al. 2001; Sagan et al. 2004;

Crisma et al. 2006; Feng et al. 2007; Storcken et al. 2007; Calaza and Cativiela 2008; Cativiela and Ordoñez 2009; Balducci et al. 2010; Nguyen et al. 2010; Iosub et al. 2010; Lu and Lin 2011; Ilies et al. 2011; Weber et al. 2012; Hugelshofer et al. 2013) represents one of the promising strategies to preferentially stabilize an ensemble of closely related bioactive conformations. Such modifications may lead to enhanced potency, better selectivity, and improvement on many of the above-mentioned shortcomings and, therefore, are largely employed within development of peptide-based therapeutics.




Within this topic, we already reported about the stereoselective synthesis of isosteres of proteinogenic amino acids, and the chiral pyrrolidin-2-one **1** was the key intermediate for preparation of **2**, a cyclic isostere of  $\beta$ -homoserine (Galeazzi et al. 2005). Moreover, alkylation of pyrrolidin-2-one **1** allowed to obtain in good yield and total stereoselection compounds **3** and **4**, the isosteres of (*R*)-2-methyl- $\beta$ -homoserine (Martelli et al. 2010) and (*R*)-2-methylaspartic acid (Crucianelli et al. 2010), respectively (Scheme 1).

## Results and discussion

We disclose here a novel approach to *ent*-**3**, already prepared in our laboratory (Galeazzi et al. 2003), exploiting a stereoselective acylation–alkylation sequence starting from the hydroxymethyl derivative **5** (Scheme 2).

Thus, the TIPS-derivative **6** was treated with LiTMP, followed by methyl chloroformate, to give in good yield and nearly total stereoselection the acylated product **7**. We were delighted to observe that the TIPS group was essential for *trans* stereoselection, since when less sterically demanding groups such as Bn or TBDMS were employed,

A. Civitavecchia · G. Martelli · M. Orena (✉) · S. Rinaldi  
Dipartimento Di.S.V.A., Università Politecnica delle Marche,  
Via Brecce Bianche, 60131 Ancona, Italy  
e-mail: m.orena@univpm.it

**Scheme 1** Isosteres prepared from lactam **1****Scheme 2** Reagents and conditions: **i** TIPSCl, imidazole, DCM, 72 %; **ii** LiTMP, THF, 0 °C, then MeOOCCl, THF, 0 °C, 86 %; **iii** *n*-BuLi, THF, 0 °C, then MeI, 72 %; **iv** 2 M NaOH, MeOH, 50 °C, then 0.2 M HCl, 95 %; **v** DPPA, *t*-BuOH, Et<sub>3</sub>N, 70 °C, 46 %; **vi** 3 M HCl, MeOH, 50 °C, then 2 M NaOH, quantitative yield; **vii** Li, NH<sub>3</sub>, -78 °C, 82 %**Scheme 3** Reagents and conditions: **i** LiOH/H<sub>2</sub>O at reflux, MeOH, then 0.1 M HCl, 64 %


the acylation reaction afforded mixtures in 60:40 and 90:10 *trans*:*cis* dr, respectively (Orena unpublished observations). Then, metalation of **7** with *n*-BuLi, followed by addition of methyl iodide, allowed to introduce the methyl group at C-3 in moderate yield but with total stereoselection. In fact, compound **8** was isolated as the sole isomer, and its configuration was unambiguously ascertained after

conversion into the corresponding lactone **12**, where the *cis*-relationship between the hydrogen at C-4 and the methyl group at C-3, expected from mechanistic considerations, was confirmed on the basis of n.o.e. experiments (Scheme 3).

Having compound **8** in hands, hydrolysis under basic conditions gave the carboxylic acid **9** that by reaction with DPPA in *t*-BuOH was converted into the carbamate **10** in moderate yield. Since prolonged treatment of **10** with fluoride anion was not effective for removal of the silyl ether, cleavage was carried out under acidic conditions, to give compound **11** where *N*-Boc group remained unaffected, probably owing to steric congestion at the quaternary center. Eventually, by treatment with Li in NH<sub>3</sub>, the chiral inducer phenylethyl group was easily removed, and the isostere *ent*-**3** was recovered in good yield.

With the aim of preparing also the 3,4-*trans*-3,3,4-trisubstituted compound **18**, again displaying (3*S*) configuration, we envisaged a synthetic strategy starting from hydroxymethyl derivative **13** (Galeazzi et al. 2003), exploiting reversal of the above-reported acylation–methylation sequence (Scheme 4).

**Scheme 4** Reagents and conditions: **i** TIPSCl, imidazole, DCM, 85 %; **ii** *n*-BuLi, THF,  $-15^{\circ}\text{C}$ , then MeI, THF,  $-15^{\circ}\text{C}$ , 71 %; **iii** *n*-BuLi, THF,  $-15^{\circ}\text{C}$ , then MeOOCCl, THF,  $-15^{\circ}\text{C}$ , 46 %; **iv** 2 M NaOH, MeOH,  $50^{\circ}\text{C}$ , then 0.2 M HCl, 98 %; **v** DPPA, *t*-BuOH,  $\text{Et}_3\text{N}$ ,  $70^{\circ}\text{C}$ , complex inseparable mixture, product **18** was missing



In fact, the silyl derivative **14**, after conversion into its lithium enolate was treated with methyl iodide to afford product **15** in good yield and with total *trans* stereoselection. Metalation at C-3 followed by addition of methyl chloroformate afforded the ester **16** in low yield, albeit with total *trans* stereoselection. After basic hydrolysis, the acid **17** was isolated in excellent yield but, in spite of many attempts carried out under different reaction conditions, and in contrast to the favorable results obtained starting from **9**, all rearrangement reactions mediated by DPPA led to complex mixtures of products, from which no identifiable material could be isolated. Thus, since both the starting acid **17** and the acylazide intermediate, initially generated by the reaction with DPPA, were missing, extended decomposition was reasonably attributed to side reactions of either the acylnitrene or the subsequent isocyanate intermediate.

## Conclusions

In summary, the 2-methylhomoserine constrained isostere *ent*-**3** was prepared exploiting a totally stereoselective acylation–alkylation sequence. Although we planned to synthesize also lactam **18**, key intermediate to a diastereomer of **3**, we were not able to achieve this goal owing to the unexpected behavior of compound **17** that decomposed under the reaction conditions. Thus, to make available all four stereoisomers of **3** a totally different approach was envisaged, and synthetic procedures currently underway will be reported in due course.

## Experimental

$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were determined on a Varian Gemini 200 spectrometer at 200 and 50 MHz for  $^1\text{H}$  and  $^{13}\text{C}$ , respectively, in  $\text{CDCl}_3$  unless otherwise reported. Chemical shifts are given as ppm from tetramethylsilane and *J* values are given in Hertz. Optical rotations,  $[\alpha]_{\text{D}}$ ,

were recorded at room temperature on a Perkin-Elmer Model 241 polarimeter at the sodium D line (concentration in g/100 mL). LC electrospray ionization mass spectra were obtained with an Agilent Technologies MSD1100 single-quadrupole mass spectrometer, eluting samples in MeOH. Elemental analyses were performed with a Carlo Erba CHN Elemental Analyzer. Column chromatography was performed using Kieselgel 60 Merck (230–400 mesh ASTM). Tetrahydrofuran and dichloromethane were distilled from sodium-benzophenone and  $\text{CaH}_2$ , respectively, under an argon atmosphere. Compounds **5** and **13** were obtained according to Galeazzi et al. (2003).

## Synthesis of silyl ethers **6** and **14**: general procedure

To a solution of 4-hydroxymethyl pyrrolidin-2-ones **5** or **13** (1.25 g, 5.73 mmol) dissolved in dry DCM (6 mL) at rt under inert atmosphere, imidazole (430 mg, 6.3 mmol) and TIPSCl (1.3 mL, 6.3 mmol) were added. After 8 h, the reaction mixture was poured into  $\text{H}_2\text{O}$ -ice and extracted with ethyl acetate ( $3 \times 50$  mL). The organic layer was dried ( $\text{Na}_2\text{SO}_4$ ) and volatiles removed under reduced pressure. The residue was then purified on silica gel (cyclohexane:ethyl acetate 80:20) to give the corresponding silyl ethers **6** and **14** as colorless oils.

(*R*)-1-((*S*)-1-Phenylethyl)-4-(((triisopropylsilyl)oxy)methyl)pyrrolidin-2-one, **6**

Compound **6** (1.55 g, 72 % yield):  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ):  $\delta$  0.96 (m, 21H), 1.52 (d, *J* = 7.4, 3H), 2.18–2.33 (m, 1H), 2.44–2.59 (m, 2H), 2.89 (dd, *J* = 4.8, *J* = 10.0, 1H), 3.36 (dd, *J* = 7.6, *J* = 10.0, 1H), 3.40–3.57 (m, 2H), 5.50 (q, *J* = 7.4, 1H), 7.18–7.27 (m, 5 ArH).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ ):  $\delta$  11.7, 16.0, 17.8, 33.5, 34.0, 44.4, 48.8, 64.5, 127.0, 127.3, 128.4, 140.0, 173.6.  $[\alpha]_{\text{D}}$  81.8 (c 1.1,  $\text{CHCl}_3$ ). MS (ESI): *m/z* 375.4  $[\text{M}]^+$ , 398.4  $[\text{M} + \text{Na}]^+$ . Anal. calcd for  $\text{C}_{22}\text{H}_{37}\text{NO}_2\text{Si}$ : C 70.35; H 9.93; N 3.73. Found: C, 70.25; H, 9.84; N, 3.69.

(3*R*,4*R*)-Methyl 2-oxo-1-((*S*)-1-phenylethyl)-4-(((triisopropylsilyl)oxy)methyl)pyrrolidine-3-carboxylate, **7**

Compound **6** (1.02 g, 2.7 mmol) was dissolved in dry THF (10 mL) under inert atmosphere at 0 °C and tetramethylpiperidine (0.5 mL, 2.9 mmol) and *n*-BuLi (5.2 mmol, 5.2 mL of a 1 M solution in hexane) were sequentially added. After 15 min methyl chloroformate (0.22 mL, 2.9 mmol) was slowly added and the mixture was stirred for 15 min at 0 °C. After quick sequential addition of H<sub>2</sub>O (100 mL) and ethyl acetate (100 mL), the organic phase was separated, and then the aqueous phase was extracted with additional ethyl acetate (2 × 100 mL). The organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and volatiles were removed under reduced pressure. The residue was purified by silica gel chromatography (cyclohexane:ethyl acetate 90:10) to give compound **7** in 86 % yield (1.01 g, 2.3 mmol) as a colorless oil. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): δ 0.95 (m, 21H), 1.54 (d, *J* = 7.4, 3H), 2.78–2.92 (m, 2H), 3.38–3.46 (m, 2H), 3.50–3.61 (m, 2H), 3.79 (s, 3H), 5.49 (q, *J* = 7.4, 1H), 7.24–7.30 (m, 5ArH). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 14.7, 15.9, 17.8, 38.1, 42.8, 49.5, 51.2, 52.5, 63.0, 127.0, 127.3, 127.5, 128.5, 139.5, 168.7, 170.3. [α]<sub>D</sub> –25.0 (c 1, CHCl<sub>3</sub>). MS (ESI): *m/z* 433.3 [M]<sup>+</sup>, 456.3 [M + Na]<sup>+</sup>. Anal. calcd for C<sub>24</sub>H<sub>39</sub>NO<sub>4</sub>Si: C, 66.47; H, 9.06; N, 3.23. Found: C, 66.38; H, 9.00; N, 3.18.

(3*S*,4*R*)-Methyl 3-methyl-2-oxo-1-((*S*)-1-phenylethyl)-4-(((triisopropylsilyl)oxy)methyl)pyrrolidine-3-carboxylate, **8**

To a solution of compound **7** (1.01 g, 2.3 mmol) in dry THF (10 mL) under inert atmosphere at 0 °C, *n*-BuLi (2.5 mmol, 2.5 mL of a 1 M solution in hexane) was added and the mixture was stirred for 15 min at 0 °C. Then, methyl iodide (156 μL, 2.5 mmol) was added and the mixture was stirred for a further 10 min at 0 °C. After quick sequential addition of H<sub>2</sub>O (100 mL) and ethyl acetate (100 mL), the organic phase was separated, and then the aqueous phase was extracted with additional ethyl acetate (2 × 100 mL). The organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and volatiles were removed under reduced pressure. The residue was eventually purified by silica gel chromatography (cyclohexane:ethyl acetate 80:20) to give the title product **8** (745 mg; 72 % yield) as a colorless oil. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): δ 0.98 (m, 21H), 1.49 (s, 3H), 1.57 (d, *J* = 7.2, 3H), 2.35–2.47 (m, 1H), 2.77 (dd, *J* = 9.0, *J* = 9.6, 1H), 3.29 (dd, *J* = 8.0, *J* = 9.6, 1H), 3.46 (dd, *J* = 8.0, *J* = 10.0, 1H), 3.55 (s, 3H), 3.73 (dd, *J* = 6.6, *J* = 10.0, 1H), 5.55 (q, *J* = 7.2, 1H), 7.29–7.36 (m, 5 ArH). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 11.6, 15.7, 17.5, 17.7, 20.5, 43.5, 45.7, 49.6, 53.1, 55.3, 61.8, 126.4,

126.7, 127.3, 128.0, 128.5, 138.7, 173.2, 173.9. [α]<sub>D</sub> –70.8 (c 1, CHCl<sub>3</sub>). MS (ESI): *m/z* 447.3 [M]<sup>+</sup>, 470.4 [M + Na]<sup>+</sup>. Anal. calcd for C<sub>25</sub>H<sub>41</sub>NO<sub>4</sub>Si: C, 67.07; H, 9.23; N, 3.13. Found: C, 66.98; H, 9.10; N, 3.19.

(3*S*,4*R*)-3-Methyl-2-oxo-1-((*S*)-1-phenylethyl)-4-(((triisopropylsilyl)oxy)methyl)pyrrolidine-3-carboxylic acid, **9**

To a solution containing the ester **8** (675 mg, 1.5 mmol) in MeOH (8 mL) 2 M NaOH (8 mL) was added at rt. The mixture was heated at 50 °C for 3 h and then, after cooling to rt, 0.2 M HCl (85 mL) was added. The reaction mixture was extracted with ethyl acetate (3 × 50 mL) and the organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>). Solvents were removed under reduced pressure and the title product **9** was recovered (620 mg; 95 % yield) as a colorless oil. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): δ 0.95 (m, 21H), 1.53 (s, 3H), 1.56 (d, *J* = 7.2, 3H), 2.34–2.36 (m, 1H), 3.05 (dd, *J* = 4.8, *J* = 10.2, 1H), 3.39 (dd, *J* = 7.4, *J* = 10.2, 1H), 3.52 (dd, *J* = 8.2, *J* = 9.8, 1H), 3.79 (dd, *J* = 5.0, *J* = 9.8, 1H), 5.44 (q, *J* = 7.2, 1H), 7.26–7.34 (m, 5 ArH), 9.17 (bs, 1H, COOH). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 11.4, 15.9, 17.3, 17.5, 20.6, 43.5, 45.7, 49.6, 53.1, 61.9, 126.6, 126.9, 127.2, 128.1, 128.3, 138.5, 173.4, 173.8. [α]<sub>D</sub> –40.1 (c 1, CHCl<sub>3</sub>). MS (ESI): *m/z* 433.4 [M]<sup>+</sup>, 456.4 [M + Na]<sup>+</sup>. Anal. calcd for C<sub>24</sub>H<sub>39</sub>NO<sub>4</sub>Si: C, 66.47; H, 9.06; N, 3.23. Found: C, 66.43; H, 9.11; N, 3.17.

*tert*-Butyl ((3*S*,4*S*)-3-methyl-2-oxo-1-((*S*)-1-phenylethyl)-4-(((triisopropylsilyl)oxy)methyl)pyrrolidin-3-yl)carbamate, **10**

To a solution containing compound **9** (319 mg, 1.05 mmol) in *t*-BuOH (3 mL), DPPA (363 μL, 1.68 mmol) and Et<sub>3</sub>N (234 μL, 1.68 mmol) were added and the mixture was heated at 70 °C for 8 h. After cooling, water (15 mL) was added, and then the mixture was extracted with ethyl acetate (2 × 30 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), solvents were removed under reduced pressure, and the residue was purified by silica gel chromatography (cyclohexane:ethyl acetate 70:30) to give compound **10** (245 mg, 46 % yield) as colorless oil. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): δ 0.90 (m, 21H), 1.51 (s, 3H), 1.53 (d, *J* = 7.4, 3H), 2.51–2.70 (m, 1H), 3.10 (dd, *J* = 9.5, *J* = 9.8, 1H), 3.21–3.50 (m, 2H), 3.58 (dd, *J* = 4.6, *J* = 9.8, 1H), 5.39 (q, *J* = 7.4, 1H), 5.72 (s, 1H, NH), 7.19–7.35 (m, 5 ArH). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 11.8, 16.1, 17.8, 20.2, 43.6, 46.7, 49.5, 51.8, 54.1, 62.4, 127.3, 127.4, 128.2, 128.5, 139.3, 171.1, 173.0. [α]<sub>D</sub> 48.4 (c 0.6, CHCl<sub>3</sub>). MS (ESI): *m/z* 504.3 [M]<sup>+</sup>, 527.3 [M + Na]<sup>+</sup>. Anal. calcd for C<sub>28</sub>H<sub>48</sub>N<sub>2</sub>O<sub>4</sub>Si: C, 66.62; H, 9.58; N, 5.55. Found: C, 66.53; H, 9.51; N, 5.47.

*t*-Butyl ((3*S*,4*S*)-4-(hydroxymethyl)-3-methyl-2-oxo-1-((*S*)-1-phenylethyl)pyrrolidin-3-yl)carbamate, **11**

To a solution containing compound **10** (218 mg, 0.43 mmol) in MeOH (1.0 mL), 3 M HCl (1.0 mL) was added and the mixture was stirred at 50 °C for 1.5 h and then at rt for 12 h. After addition of 2 M NaOH (2 mL), the mixture was extracted with ethyl acetate (2 × 20 mL), the organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), and removal of volatiles under reduced pressure gave a residue that after silica gel chromatography (cyclohexane:ethyl acetate 50:50) afforded product **11** (140 mg, 95 % yield) as a viscous colorless oil. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>):  $\delta$  1.05 (s, 9H), 1.47 (s, 3H), 1.55 (d,  $J$  = 7.4, 3H), 2.42–2.54 (m, 1H), 2.70 (dd,  $J$  = 3.2,  $J$  = 10.6, 1 H), 3.44 (dd,  $J$  = 7.2,  $J$  = 10.6, 1H), 3.74 (dd,  $J$  = 8.6,  $J$  = 11.8, 1H), 4.09 (dd,  $J$  = 4.8,  $J$  = 11.8, 1H), 5.45 (q,  $J$  = 7.4, 1H), 5.48 (br s, 1H, NH), 7.18–7.39 (m, 5 ArH). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>):  $\delta$  12.1, 15.5, 17.5, 23.6, 34.9, 40.2, 49.2, 59.3, 64.7, 126.7, 127.8, 128.2, 128.3, 138.5, 153.0, 172.4. [ $\alpha$ ]<sub>D</sub> –86.7 (c 1.5, CHCl<sub>3</sub>). MS (ESI):  $m/z$  348.2 [M]<sup>+</sup>, 371.2 [M + Na]<sup>+</sup>. Anal. calcd for C<sub>19</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub>: C, 65.49; H, 8.10; N, 8.04. Found: C, 65.43; H, 8.01; N, 8.13.

*t*-Butyl ((3*S*,4*S*)-4-(hydroxymethyl)-3-methyl-2-oxopyrrolidin-3-yl)carbamate, ent-**3**

Ammonia (about 4 mL) was condensed in a three-necked flask at –78 °C, Li shots (14 mg, 2.0 mmol) were added, and the blue solution was stirred at this temperature for 20 min. Then compound **11** (105 mg, 0.3 mmol) was dissolved in a mixture of dry THF (0.9 mL) and *t*-BuOH (0.1 mL), and the solution added in one portion. After 3 min, the reaction mixture was quenched by addition of solid NH<sub>4</sub>Cl (200 mg) and warmed to room temperature. Then ammonia was removed, ethyl acetate (10 mL) and water (3 mL) added, the mixture extracted with ethyl acetate (2 × 20 mL) and the combined organic layers dried over Na<sub>2</sub>SO<sub>4</sub>. After the solvent was removed in vacuo, the crude product was purified by silica gel chromatography (cyclohexane:ethyl acetate 40:60 as eluent) to give ent-**3** (60 mg, 82 % yield) as a colorless oil. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>):  $\delta$  1.42 (s, 9H), 1.47 (s, 3H), 2.53–2.63 (m, 1H), 3.00 (br s, 1H, OH), 3.42 (d,  $J$  = 4.8, 2H), 3.52 (dd,  $J$  = 6.7,  $J$  = 11.1, 1H), 3.68 (dd,  $J$  = 4.9,  $J$  = 11.1, 1H), 5.27 (br s, 1H, NH), 6.70 (br s, 1H, NH). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>):  $\delta$  22.5, 28.2, 42.1, 46.6, 58.2, 61.2, 79.9, 155.4, 177.8. [ $\alpha$ ]<sub>D</sub> 49.6 (c 0.6, CHCl<sub>3</sub>) [Lit. –50.0 (c 0.6, CHCl<sub>3</sub>) (Martelli et al. 2010)]. MS (ESI):  $m/z$  244.3 [M]<sup>+</sup>, 267.3 [M + Na]<sup>+</sup>. Anal. calcd for C<sub>11</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>: C, 54.08; H, 8.25; N, 11.47. Found: C, 54.98; H, 8.19; N, 11.55.

(3*aR*,6*aS*)-6*a*-Methyl-5-((*S*)-1-phenylethyl)tetrahydro-1*H*-furo[3,4-*c*]pyrrole-1,6(6*aH*)-dione, **12**

The pyrrolidin-2-one **8** (100 mg, 0.22 mmol) was dissolved in MeOH (1 mL) containing LiOH·H<sub>2</sub>O (0.28 mmol, 12 mg) and the mixture was refluxed for 5 h. After removal of the solvent under reduced pressure, 0.1 M HCl (2.8 mL) was added, and the mixture was extracted with ethyl acetate (3 × 5 mL). After drying (Na<sub>2</sub>SO<sub>4</sub>) and removal of the solvent, compound **12** (37 mg, 64 % yield) was obtained as a yellow oil. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>):  $\delta$  1.53 (s, 3H), 1.56 (d,  $J$  = 7.2 Hz, 3H), 2.76 (dd,  $J$  = 2.1 Hz,  $J$  = 10.8 Hz, 1H), 2.92 (m, 1H), 3.53 (dd,  $J$  = 6.6 Hz,  $J$  = 10.8 Hz, 1H), 3.60 (dd,  $J$  = 6.9 Hz,  $J$  = 9.6 Hz, 1H), 4.38 (dd,  $J$  = 8.4 Hz,  $J$  = 9.6 Hz, 1H), 5.50 (q,  $J$  = 7.2 Hz, 1H), 7.26–7.37 (m, 5H, Ar). [ $\alpha$ ]<sub>D</sub> –16.3 (c 1.0, CHCl<sub>3</sub>). MS (ESI):  $m/z$ : 259.1 [M]<sup>+</sup>, 282.1 [M + Na]<sup>+</sup>. Anal. calcd for C<sub>15</sub>H<sub>17</sub>NO<sub>3</sub>: C, 69.48; H, 6.61; N, 5.40. Found: C, 69.38; H, 6.55; N, 5.33.

(S)-1-((S)-1-Phenylethyl)-4-(((triisopropylsilyl)oxy)methyl)pyrrolidin-2-one, **14**

Compound **14** (1.83 g, 85 % yield) was obtained according to the general procedure above reported. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>):  $\delta$  1.06 (m, 21H), 1.46 (d,  $J$  = 7.2, 3H), 2.22–2.57 (m, 3H), 3.02 (dd,  $J$  = 8.5,  $J$  = 9.0, 1H), 3.22 (dd,  $J$  = 5.5,  $J$  = 9.0, 1H), 3.55–3.66 (m, 2H), 5.53 (q,  $J$  = 7.2, 1H), 7.22–7.78 (m, 5 ArH). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>):  $\delta$  12.0, 16.2, 18.1, 27.0, 30.3, 33.6, 34.3, 44.6, 48.9, 64.9, 127.2, 127.5, 128.6, 140.3, 173.8. [ $\alpha$ ]<sub>D</sub> –60.0 (c 1.0, CHCl<sub>3</sub>). MS (ESI):  $m/z$  375.4 [M]<sup>+</sup>, 398.4 [M + Na]<sup>+</sup>. Anal. calcd for C<sub>22</sub>H<sub>37</sub>NO<sub>2</sub>Si: C 70.35; H 9.93; N 3.73. Found: C, 70.27; H, 9.87; N, 3.66.

(3*S*,4*S*,1'*S*)-1-(1'-Phenylethyl)-3-methyl-4-triisopropylsilyloxymethylpyrrolidin-2-one, **15**

To a solution of pyrrolidin-2-one **14** (1.02 g, 2.71 mmol) in dry THF (10 mL) under inert atmosphere at –15 °C, *n*-BuLi (3 mmol, 1.87 mL of a 1.6-M solution in hexane) was added and the mixture was stirred for 15 min at –15 °C. Then, methyl iodide (181  $\mu$ L, 2.9 mmol) was added and the mixture was stirred for a further 10 min at –15 °C. After addition of H<sub>2</sub>O (100 mL) and ethyl acetate (100 mL), the organic phase was separated, and the aqueous phase was extracted with additional ethyl acetate (2 × 100 mL). The organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and volatiles were removed under reduced pressure, and then the residue was purified by silica gel chromatography (cyclohexane:ethyl acetate 90:10) to give compound **15** (750 mg, 71 % yield) as colorless oil. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>):  $\delta$  1.08 (m, 21H), 1.22 (d,  $J$  = 7.2, 3H), 1.51 (d,

$J = 7.4$ , 3H), 1.92–2.03 (m, 1H), 2.43 (dq,  $J = 7.2$ ,  $J = 7.4$ , 1H), 2.97 (dd,  $J = 8.2$ ,  $J = 9.4$ , 1H), 3.14 (dd,  $J = 7.8$ ,  $J = 9.4$ , 1H), 3.64–3.78 (m, 2H), 5.55 (q,  $J = 7.4$ , 1H), 7.19–7.41 (m, 5 ArH).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ ):  $\delta$  11.8, 15.4, 15.9, 17.9, 39.2, 42.7, 42.8, 48.7, 63.4, 126.8, 126.9, 127.2, 128.3, 140.3, 176.2.  $[\alpha]_{\text{D}} -94.4$  (c 1,  $\text{CHCl}_3$ ). MS (ESI):  $m/z$  389.3  $[\text{M}]^+$ , 412.3  $[\text{M} + \text{Na}]^+$ . Anal. calcd for  $\text{C}_{23}\text{H}_{39}\text{NO}_2\text{Si}$ : C, 70.90; H, 10.09; N, 3.59. Found: C, 70.76; H, 9.97; N, 3.51.

(3*S*,4*S*,1'*S*)-1-(1'-Phenylethyl)-3-methyl-3-methoxycarbonyl-4-triisopropylsilyloxymethylpyrrolidin-2-one, **16**

To a solution containing pyrrolidin-2-one **15** (700 mg, 1.79 mmol) in dry THF (7 mL) at  $-15^\circ\text{C}$  under argon, *n*-BuLi (3.94 mmol, 2.46 mL of a 1.6-M solution in hexane) was added, the mixture was stirred for 15 min, and then methyl chloroformate (152  $\mu\text{L}$ , 1.97 mmol) was slowly dropped at  $-15^\circ\text{C}$ . After 10 min,  $\text{H}_2\text{O}$  (50 mL) and ethyl acetate (100 mL) were quickly added, the organic phase was separated, then the aqueous phase was extracted with additional ethyl acetate ( $2 \times 100$  mL). The organic layers were dried ( $\text{Na}_2\text{SO}_4$ ) and volatiles were removed under reduced pressure: then the residue was purified by silica gel chromatography (cyclohexane:ethyl acetate 90:10) to give compound **16** (370 mg, 46 % yield) as a colorless oil.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ):  $\delta$  0.98 (m, 21H), 1.49 (s, 3H), 1.55 (d,  $J = 7.4$ , 3H), 2.21–2.42 (m, 1H), 3.00 (dd,  $J = 8.3$ ,  $J = 8.9$ , 1H), 3.19 (dd,  $J = 8.6$ ,  $J = 8.9$ , 1H), 3.58 (dd,  $J = 8.0$ ,  $J = 10.2$ , 1H), 3.71 (s, 3H), 3.79 (dd,  $J = 7.0$ ,  $J = 10.2$ , 1H), 5.49 (q,  $J = 7.4$ , 1H), 7.18–7.41 (m, 5 ArH).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ ):  $\delta$  12.2, 16.4, 18.0, 21.0, 27.4, 41.0, 44.5, 48.2, 52.5, 55.7, 64.8, 127.3, 127.6, 127.7, 128.7, 140.3, 171.1, 172.1.  $[\alpha]_{\text{D}} 19.8$  (c 1,  $\text{CHCl}_3$ ). MS (ESI):  $m/z$  447.3  $[\text{M}]^+$ , 470.3  $[\text{M} + \text{Na}]^+$ . Anal. calcd for  $\text{C}_{25}\text{H}_{41}\text{NO}_4\text{Si}$ : C 67.07; H 9.23; N 3.13. Found: C 67.16; H 9.27; N 3.01.

(3*S*,4*S*)-3-Methyl-2-oxo-1-((*S*)-1-phenylethyl)-4-(((triisopropylsilyl)oxy)methyl)pyrrolidine-3-carboxylic acid, **17**

To a solution containing the ester **16** (360 mg, 0.8 mmol) in MeOH (3 mL) 2 M NaOH (3 mL) was added at rt. The mixture was heated at  $50^\circ\text{C}$  for 3 h and then, after cooling, 0.2 M HCl (31 mL) was added. The reaction mixture was extracted with ethyl acetate ( $3 \times 30$  mL) and the organic layer was dried ( $\text{Na}_2\text{SO}_4$ ). Solvents were removed under reduced pressure and the title product **17** was recovered (340 mg, 98 % yield) as a colorless oil.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.03 (m, 21H), 1.42 (s, 3H), 1.54 (d,  $J = 7.2$ , 3H), 2.21–2.31 (m, 1H), 3.08 (dd,  $J = 7.2$ ,

$J = 10.5$ , 1H), 3.31 (dd,  $J = 2.4$ ,  $J = 10.5$ , 1H), 3.68 (dd,  $J = 2.7$ ,  $J = 9.9$ , 1H), 3.99 (dd,  $J = 5.1$ ,  $J = 9.9$ , 1H), 5.51 (q,  $J = 7.2$ , 1H), 7.20–7.43 (m, 5ArH), 7.60–8.20 (br, 1H, OH).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ ):  $\delta$  12.1, 16.2, 18.0, 21.3, 27.1, 40.6, 44.1, 48.4, 55.1, 65.0, 127.2, 127.6, 128.6, 128.7, 140.2, 170.9, 174.0.  $[\alpha]_{\text{D}} 25.1$  (c 1,  $\text{CHCl}_3$ ). MS (ESI):  $m/z$  433.3  $[\text{M}]^+$ , 456.3  $[\text{M} + \text{Na}]^+$ . Anal. calcd for  $\text{C}_{24}\text{H}_{39}\text{NO}_4\text{Si}$ : C, 66.47; H, 9.06; N, 3.23. Found: C, 66.55; H, 9.18; N, 3.11.

**Acknowledgments** Funds from Università Politecnica delle Marche (Ancona, Italy) are gratefully acknowledged.

**Conflict of interest** The authors declare no conflicts of interest.

## References

- Balducci D, Lazzari I, Monari M, Piccinelli F, Porzi G (2010) (*S*)- $\alpha$ -methyl,  $\alpha$ -amino acids: a new stereocontrolled synthesis. *Amino Acids* 38:829–837
- Benedetti E (1996) X-ray crystallography of peptides: the contributions of the Italian laboratories. *Pept Sci* 40:3–44
- Boy KM, Guernon JM, Shi J, Toyn JH, Meredith JE, Barten DM, Burton CR, Albright CF, Marcinkeviciene J, Good AC, Tebben AJ, Muckelbauer JK, Camac DM, Lentz KA, Bronson JJ, Olson RE, Macor JE, Thompson LA III (2011) Monosubstituted  $\gamma$ -lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of  $\beta$ -secretase (BACE). *Bioorg Med Chem Lett* 21:6916–6924
- Broadrup RL, Wang B, Malachowski WP (2005) A general strategy for the synthesis of azapeptidomimetic lactams. *Tetrahedron* 61:10277–10284
- Calaza MI, Cativiela C (2008) Stereoselective synthesis of quaternary proline analogues. *Eur J Org Chem* 20:3427–3448
- Cativiela C, Ordoñez M (2009) Recent progress on the stereoselective synthesis of cyclic quaternary  $\alpha$ -amino acids. *Tetrahedron Asymmetry* 20:1–63
- Crisma M, Formaggio F, Moretto A, Toniolo C (2006) Peptide helices based on  $\alpha$ -amino acids. *Pept Sci* 84:3–12
- Crucianelli E, Galeazzi R, Martelli G, Orena M, Rinaldi S, Sabatino P (2010) A novel conformationally restricted analogue of 3-methylaspartic acid via stereoselective methylation of chiral pyrrolidin-2-ones. *Tetrahedron* 66:400–405
- Dolbeare K, Pontoriero GF, Gupta SK, Mishra RK, Johnson RL (2003) Synthesis and dopamine receptor modulating activity of 3-substituted  $\gamma$ -lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide. *J Med Chem* 46:727–733
- Feng JA, Tessler LA, Marshall GR (2007) Chimeric protein engineering. *Int J Pept Res Ther* 13:151–160
- Freidinger RM (2003) Design and synthesis of novel bioactive peptides and peptidomimetics. *J Med Chem* 46:5553–5566
- Galaud F, Lubell WD (2005) Homoserine-derived cyclic sulfamidate as chiral educt for the diversity-oriented synthesis of lactam-bridged dipeptides. *Biopolymers* 80:665–674
- Galeazzi R, Martelli G, Mobbili G, Orena M, Panagiotaki M (2003) A stereoselective approach to both 3,4-*trans*-disubstituted pyrrolidin-2-ones and pyrrolidines. A convenient synthesis of (3*R*,4*R*)-4-benzyl-3-pyrrolidinecarboxylic acid. *Heterocycles* 60:2485–2498
- Galeazzi R, Martelli G, Natali D, Orena M, Rinaldi S (2005) Chiral 3-hydroxypyrrolidin-2-ones. Part 2: stereodivergent synthesis of conformationally restricted analogues of  $\beta$ -homoserine. *Tetrahedron Asymmetry* 16:1779–1787

- Hanessian S, Auzzas L (2008) The practice of ring constraint in peptidomimetics using bicyclic and polycyclic amino acids. *Acc Chem Res* 41:1241–1251
- Hugelshofer CL, Mellem KT, Myers AG (2013) Synthesis of quaternary  $\alpha$ -methyl  $\alpha$ -amino acids by asymmetric alkylation of pseudoephedrine alaninamide pivaldimine. *Org Lett* 15:3134–3137
- Ilies M, Di Costanzo L, Dowling DP, Thorn KJ, Christianson DW (2011) Binding of  $\alpha,\alpha$ -disubstituted amino acids to arginase suggests new avenues for inhibitor design. *J Med Chem* 54:5432–5443
- Iosub V, Haberl AR, Leung J, Tang M, Vembaiyan K, Parvez M, Back TG (2010) Enantioselective Synthesis of  $\alpha$ -quaternary amino acid derivatives by sequential enzymatic desymmetrization and Curtius rearrangement of  $\alpha,\alpha$ -disubstituted malonate diesters. *J Org Chem* 75:1612–1619
- Jamieson AG, Boutard N, Beauregard K, Bodas Mandar S, Ong H, Quiniou C, Chemtob S, Lubell WD (2009) Positional scanning for peptide secondary structure by systematic solid-phase synthesis of amino lactam peptides. *J Am Chem Soc* 131:7917–7927
- Lesma G, Landoni N, Pilati T, Sacchetti A, Silvani A (2009) Tetrahydroisoquinoline-based spirocyclic lactam as a type II'  $\beta$ -turn inducing peptide mimetic. *J Org Chem* 74:8098–8105
- Lu T-J, Lin C-K (2011) Asymmetric synthesis of  $\alpha$ -methyl- $\alpha$ -amino acids via diastereoselective alkylation of (1*S*)-(+)-3-carene derived tricyclic iminolactone. *J Org Chem* 76:1621–1633
- Martelli G, Orena M, Rinaldi S, Sabatino P (2010) Diastereoselective functionalisation of Baylis–Hillman adducts: a convenient approach to  $\alpha$ -methyl- $\alpha$ -amino acids. *Amino Acids* 39:489–497
- Nguyen TB, Beauseigneur A, Martel A, Dhal R, Laurent M, Dujardin G (2010) Access to  $\alpha$ -substituted amino acid derivatives via 1,3-dipolar cycloaddition of  $\alpha$ -amino ester derived nitrones. *J Org Chem* 75:611–620
- Otvos F, Gembitsky DS, Murphy RF, Lovas S (2007) Synthesis and structure–activity relationship of [Nle<sup>10</sup>]Neurokinin A (4–10) analogs with constraint in the backbone and at position six. *Int J Pept Res Ther* 13:329–336
- Perdih H, Kikelj D (2006) The application of Freidinger lactams and their analogs in the design of conformationally constrained peptidomimetics. *Curr Med Chem* 13:1525–1556
- Sagan S, Karoyan P, Lequin O, Chassaing G, Lavielle S (2004) N- and C $\alpha$ -methylation in biologically active peptides: synthesis, structural and functional aspects. *Curr Med Chem* 11:2799–2822
- Seufert W, Fleury A, Giese B (2006) Cyclizations of  $\alpha$ -keto ester modified aspartic acids in peptides. *Synlett* 11:1774–1776
- St-Cyr DJ, Jamieson AG, Lubell WD (2010)  $\alpha$ -Amino- $\beta$ -hydroxy- $\gamma$ -lactam for constraining peptide Ser and Thr residue conformation. *Org Lett* 12:1652–1655
- Storcken RPM, Panella L, van Delft FL, Kaptein B, Broxterman QB, Schoemaker HE, Rutjes FPJT (2007) A cross-metathesis route to functionalized  $\alpha$ -methyl  $\alpha$ -substituted amino acids. *Adv Synth Catal* 349:161–164
- Toniolo C, Crisma M, Formaggio F, Peggion C (2001) Control of peptide conformation by the Thorpe–Ingold effect (C $\alpha$ -tetrasubstitution). *Pept Sci* 60:396–419
- Virlouvet M, Podlech J (2010)  $\gamma$ -Lactam-containing peptidomimetics. *Tetrahedron* 66:6174–6180
- Weber M, Frey W, Peters R (2012) Catalytic asymmetric synthesis of functionalized  $\alpha,\alpha$ -disubstituted  $\alpha$ -amino acid derivatives from racemic unprotected  $\alpha$ -amino acids via in situ generated azlactones. *Adv Synth Catal* 354:1443–1449